First-in-Human Phase I Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Antitumor Activity - Concepedia

Concepedia

Publication | Closed Access

First-in-Human Phase I Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Antitumor Activity

60

Citations

21

References

2019

Year

Hui Gan, Michael Millward, Hua Ye, Chuan Qi, Yang Sai, Weiguo Su, Jian Wang, Zhang Li-lin, Melanie M. Frigault, Shethah Morgan,

Clinical Cancer Research

Abstract

The tolerability profile of savolitinib was acceptable and the RP2D was established as 600 mg QD. Preliminary antitumor activity was demonstrated supporting further study in patients with PRCC.

References

	Year	Citations

Page 1